Hyperuricemia and reduced glomerular filtration rate in the population among Nizhny Novgorod region inhabitants


DOI: https://dx.doi.org/10.18565/therapy.2023.3.36-43

Borovkova N.Yu., Kurashin V.K., Tokareva A.S., Makarova E.V., Nekrasov A.A., Savitskaya N.N., Mironov M.A.

1) Privolzhsky Research Medical University of the Ministry of Healthcare of Russia, Nizhny Novgorod; 2) Nizhny Novgorod Regional Center for Public Health and Medical Prevention
Abstract. There is information in the literature about the association of hyperuricemia (HU) with a wide range of chronic non-infectious diseases. At the same time, the prevalence of HU and its correlation with a decrease in glomerular filtration rate (GFR) among the population of the Nizhny Novgorod region has not been studied enough.
The aim of the research is to evaluate the prevalence of HU and its correlation with GFR decrease and some cardiovascular risk factors among the population of Nizhny Novgorod region.
Material and methods. 2501 persons aged 35–74 among the population of Nizhny Novgorod region were examined. In all of them anthropometric parameters, blood pressure and heart rate were measured. A laboratory study was carried out, it included measurement of indexes of the lipid spectrum, glucose, creatinine, uric acid (UA), acute phase proteins. GFR was calculated using the CKD-EPI formula. The binary logistic regression method was used to build a predictive model of HU risk.
Results. HU was detected in 23,1% of the adult population of the Nizhny Novgorod region. The group of respondents with HU had a worse metabolic and clinical profile comparatively to those individuals whose UA levels were within the normal range. GFR index in this category of persons turned out to be lower than in those surveyed who had no HU. The following factors turned out to be the most prognosticating for the risk of HU: reduced GFR in the respondent (OR 3,383; 95% CI: 2,334–4,903; p <0,001), presence of arterial hypertension (OR 1,767; 95% CI: 1,384–2,254; p< 0,001), elevated levels of highly sensitive C-reactive protein (OR 1,936; 95% CI: 1,546–2,425; p <0,001).
Conclusion. A significant number of Nizhny Novgorod region residents had an elevated level of UA. The risk factors most closely associated with HU were reduced GFR, presence of arterial hypertension, and elevated levels of highly sensitive C-reactive protein.
Keywords: uric acid, hyperuricemia, chronic kidney disease, cardiovascular disease, risk factors
Read entire article

Literature

1. Glantzounis G.K., Tsimoyiannis E.C., Kappas A.M. et al. Uric acid and oxidative stress. Curr Pharm Des. 2005; 11(32): 4145–51. https://dx.doi.org/10.2174/138161205774913255.


2. Chen F., Yuan L., Xu T. et al. Association of hyperuricemia with 10-year atherosclerotic cardiovascular disease risk among Chinese adults and elders. Int J Environ Res Public Health. 2022; 19(11): 6713. https://dx.doi.org/10.3390/ijerph19116713.


3. Кобалава Ж.Д., Конради А.О., Недогода С.В. c соавт. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(3): 149–218. [Kobalava Z.D., Konradi A.O., Nedogoda S.V. et al. Arterial hypertension in adults. Clinical guidelines 2020. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020; 25(3): 149–218 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2020-3-3786. EDN: TCRBRB.


4. Pascart T., Liote F. Gout: State of the art after a decade of developments. Rheumatology (Oxford). 2019; 58(1): 27–44. https://dx.doi.org/10.1093/rheumatology/key002.


5. Song P., Wang H., Xia W. et al. Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China. Sci Rep. 2018; 8(1): 4314. https://dx.doi.org/10.1038/s41598-018-22570-9.


6. Stewart D.J., Langlois V., Noone D. Hyperuricemia and hypertension: Links and risks. Integr Blood Press Control. 2019; 12: 43-62. https://dx.doi.org/10.2147/IBPC.S184685.


7. Yip K., Cohen R.E., Pillinger M.H. Asymptomatic hyperuricemia: is it really asymptomatic? Curr Opin Rheumatol. 2020; 32(1): 71–79. https://dx.doi.org/10.1097/BOR.0000000000000679.


8. Waheed Y., Yang F., Sun D. Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease. Korean J Intern Med. 2021; 36(6): 1281–93. https://dx.doi.org/10.3904/kjim.2020.340.


9. Chen-Xu M., Yokose C., Rai S.K. et al. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007–2016. Arthritis Rheumatol. 2019; 71(6): 991–99. https://dx.doi.org/10.1002/art.40807.


10. Liu R., Han C., Wu D. et al. Prevalence of hyperuricemia and gout in Mainland China from 2000 to 2014: A systematic review and meta-analysis. Biomed Res Int. 2015; 2015: 762820. https://dx.doi.org/10.1155/2015/762820.


11. Швабская О.Б., Измайлова О.В., Карамнова Н.С. с соавт. Гиперурикемия: особенности рациона питания. Рациональная фармакотерапия в кардиологии. 2021; 17(6): 889–899. [Shvabskaia O.B., Izmailova O.V., Karamnova N.S. et al. Hyperuricemia: Features of the Diet. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2021; 17(6): 889–899 (In Russ.)]. https://dx.doi.org/10.20996/1819-6446-2021-12-04. EDN: AXQSCI.


12. Srivastava A., Kaze A.D., McMullan C.J. et al. Uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis. 2018; 71(3): 362–70. https://dx.doi.org/10.1053/j.ajkd.2017.08.017.


13. Oliveira I.O., Mintem G.C., Oliveira P.D. et al. Uric acid is independent and inversely associated to glomerular filtration rate in young adult Brazilian individuals. Nutr Metab Cardiovasc Dis. 2020; 30(8): 1289–98. https://dx.doi.org/10.1016/j.numecd.2020.04.016.


14. Шальнова С.А., Деев А.Д., Артамонова Г.В. с соавт. Гиперурикемия и ее корреляты в российской популяции (результаты эпидемиологического исследования ЭССЕ-РФ). Рациональная фармакотерапия в кардиологии. 2014; 10(2): 153–159. [Shalnova S.A., Deev A.D., Artamonov G.V. et al. Hyperuricemia and its correlates in the Russian population (results of ESSE-RF EPIDEMIOLOGICAL study). Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2014; 10(2): 153–159 (In Russ.)]. https://dx.doi.org/10.20996/1819-6446-2014-10-2-153-159. EDN: SCOUHN.


15. Драпкина О.М., Шальнова С.А., Имаева А.Э. с соавт. Эпидемиология сердечно-сосудистых заболеваний и их факторов риска в регионах Российской Федерации. Третье исследование (ЭССЕ-РФ-3). Обоснование и дизайн исследования. Кардиоваскулярная терапия и профилактика. 2022; 21(5): 48–57. [Drapkina O.M., Shalnova S.A., Imaeva A.E. et al. Epidemiology of cardiovascular diseases in regions of Russian Federation. Third survey (ESSE-RF-3). Rationale and study design. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2022; 21(5): 48–57 (In Russ.)]. https://dx.doi.org/10.15829/1728-8800-2022-3246. EDN EZUGUW.


16. Amato M.C., Giordano C., Galia M. et al. Visceral adiposity index: A reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010; 33(4): 920–22. https://dx.doi.org/10.2337/dc09-1825.


17. Levey A.S., Stevens L.A., Schmid C.H. et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9): 604–12. https://dx.doi.org/10.7326/0003-4819-150-9-200905050-00006.


18. Amato M.C., Giordano C., Pitrone M. et al. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis. 2011; 10: 183. https://dx.doi.org/10.1186/1476-511X-10-183.


19. Vidal-Petiot E., Ford I., Greenlaw N. et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: An international cohort study. Lancet. 2016; 388(10056): 2142–52. https://dx.doi.org/10.1016/S0140-6736(16)31326-5.


20. Yang W.Y., Melgarejo J.D., Thijs .L et al. Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes. JAMA. 2019; 322(5): 409–20. https://dx.doi.org/10.1001/jama.2019.9811.


21. Tadic M., Cuspidi C., Grassi G. Heart rate as a predictor of cardiovascular risk. Eur J Clin Invest. 2018; 48(3). https://dx.doi.org/10.1111/eci.12892.


22. Han M., Qin P., Li Q. et al. Chinese visceral adiposity index: A reliable indicator of visceral fat function associated with risk of type 2 diabetes. Diabetes Metab Res Rev. 2021; 37(2): e3370. https://dx.doi.org/10.1002/dmrr.3370.


23. Hamzeh B., Pasdar Y., Mirzaei N. et al. Visceral adiposity index and atherogenic index of plasma as useful predictors of risk of cardiovascular diseases: evidence from a cohort study in Iran. Lipids Health Dis. 2021; 20(1): 82. https://dx.doi.org/10.1186/s12944-021-01505-w.


24. Neaton J.D., Blackburn H., Jacobs D. et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992; 152(7): 1490–500.


25. Esan O., Wierzbicki A.S. Triglycerides and cardiovascular disease. Curr Opin Cardiol. 2021; 36(4): 469–77. https://dx.doi.org/10.1097/HCO.0000000000000862.


26. Chapman M.J., Ginsberg H.N., Amarenco P. et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management. Eur Heart J. 2011; 32(11): 1345–61. https://dx.doi.org/10.1093/eurheartj/ehr112.


27. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018; 23(6): 7–122. [Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2018; 23(6): 7–122 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2018-6-7-122. EDN: XSLTTF.


28. Badimon L., Pena E., Arderiu G. et al. C-reactive protein in atherothrombosis and angiogenesis. Front Immunol. 2018; 9: 430. https://dx.doi.org/10.3389/fimmu.2018.00430.


29. Zhang W., Speiser J.L., Ye F. et al. High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a): Multi-ethnic study of atherosclerosis. J Am Coll Cardiol. 2021; 78(11): 1083–94. https://dx.doi.org/10.1016/j.jacc.2021.07.016.


30. Surma S., Banach M. Fibrinogen and atherosclerotic cardiovascular diseases – Review of the literature and clinical studies. Int J Mol Sci. 2021; 23(1): 193. https://dx.doi.org/10.3390/ijms23010193.


31. Robinson P.C. Gout – An update of aetiology, genetics, co-morbidities and management. Maturitas. 2018; 118: 67–73. https://dx.doi.org/10.1016/j.maturitas.2018.10.012.


32. Anton F.M., Garcia Puig J., Ramos T. et al. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. Metabolism. 1986; 35(4): 343–48. https://dx.doi.org/10.1016/0026-0495(86)90152-6.


33. Jung J.H., Song G.G., Lee Y.H. et al. Serum uric acid levels and hormone therapy type: A retrospective cohort study of postmenopausal women. Menopause. 2018; 25(1): 77–81. https://dx.doi.org/10.1097/GME.0000000000000953.


34. Yanai H., Adachi H., Hakoshima M. et al. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. Int J Mol Sci. 2021; 22(17): 9221. https://dx.doi.org/10.3390/ijms22179221.


35. Li L., Yang C., Zhao Y. et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014; 15: 122. https://dx.doi.org/10.1186/1471-2369-15-122.


36. Kang M.W., Chin H.J., Joo K.W. et al. Hyperuricemia is associated with acute kidney injury and all-cause mortality in hospitalized patients. Nephrology (Carlton). 2019; 24(7): 718–24. https://dx.doi.org/10.1111/nep.13559.


37. Wei J., Liu X., Xue H. et al. Comparisons of visceral adiposity index, body shape index, body mass index and waist circumference and their associations with diabetes mellitus in adults. Nutrients. 2019; 11(7): 1580. https://dx.doi.org/10.3390/nu11071580.


38. Cheng J.M., Oemrawsingh R.M., Garcia-Garcia H.M. et al. Relation of C-reactive protein to coronary plaque characteristics on grayscale, radiofrequency intravascular ultrasound, and cardiovascular outcome in patients with acute coronary syndrome or stable angina pectoris (from the ATHEROREMO-IVUS study). Am J Cardiol. 2014; 114(10): 1497–503. https://dx.doi.org/10.1016/j.amjcard.2014.08.013.


39. Roman Y.M. The Daniel K. Inouye College of Pharmacy Scripts: Perspectives on the epidemiology of gout and hyperuricemia. Hawaii J Med Public Health. 2019; 78(2): 71–76.


About the Autors

Natalya Yu. Borovkova, MD, associate professor, professor of the Department of hospital therapy and general medical practice named after V.G. Vogralik, Privolzhsky Research Medical University of the Ministry of Healthcare of Russia. Address: 603005, Nizhny Novgorod, 10/1 Minina i Pozharskogo Sq. E-mail: borovkov-nn@mail.ru. ORCID: https://orcid.org/0000-0001-7581-4138
Vladimir K. Kurashin, postgraduate student of the Department of hospital therapy and general medical practice named after V.G. Vogralik, Privolzhsky Research Medical University of the Ministry of Healthcare of Russia. Address: 603005, Nizhny Novgorod, 10/1 Minina i Pozharskogo Sq. E-mail: kurashin-vk@yandex.ru. ORCID: https://orcid.org/0000-0002-3730-583
Anastasia S. Tokareva, assistant at the Department of hospital therapy and general medical practice named after V.G. Vogralik, Privolzhsky Research Medical University of the Ministry of Healthcare of Russia. Address: 603005, Nizhny Novgorod, 10/1 Minina i Pozharskogo Sq. E-mail: toktokareva@gmail.com. ORCID: https://orcid.org/0000-0003-0640-6848
Ekaterina V. Makarova, MD, associate professor, head of the Department of propaedeutics of internal diseases and geriatrics named after K.G. Nikulin, Privolzhsky Research Medical University of the Ministry of Healthcare of Russia. Address: 603005, Nizhny Novgorod, 10/1 Minina i Pozharskogo Sq. E-mail: e_makarova@mail.ru. ORCID: https://orcid.org/0000-0003-4394-0687
Alexey A. Nekrasov, MD, associate professor, head of the Department of faculty and polyclinic therapy, Privolzhsky Research Medical University of the Ministry of Healthcare of Russia. Address: 603005, Nizhny Novgorod, 10/1 Minina i Pozharskogo Sq. E-mail: anekrassov@mail.ru. ORCID: https://orcid.org/0000-0003-3325-4405
Natalya N. Savitskaya, chief physician of Nizhny Novgorod Regional Center for Public Health and Medical Prevention. Address: 603136, Nizhny Novgorod, 209/1a Vaneeva Str. E-mail: savickaya.natalya.nn@mail.ru
Mikhail A. Mironov, student of Privolzhsky Research Medical University of the Ministry of Healthcare of Russia. Address: 603005, Nizhny Novgorod, 10/1 Minina i Pozharskogo Sq. E-mail: mironovdoctor@gmail.com


Similar Articles

Back to Content

Бионика Медиа